• Participants with IPF of any gender ≥ 40 years of age at time of signing the informed consent.

• Able to understand the study and provide signed, written informed consent.

• Able to read and understand the language of the informed consent and other trial-related materials.

• Meet the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association (ATS/ERS/JRS/ALAT) 2019 criteria for the diagnosis of IPF; Diagnosed with IPF within 7 years of screening.

• If a participant is on treatment with pirfenidone or nintedanib, the dose of the medication must be stable for ≥ 90 days prior to Screening with plans to maintain the same dose throughout the study treatment period. Use of both agents together is not permitted.

• If a participant was on treatment with nintedanib or pirfenidone, and the agent has been discontinued, this must have occurred ≥ 30 days prior to Screening. At Screening, there must also be no plan to start either of these medications for the duration of the study.

• FVC of ≥ 45 percent predicted (pp) at screening.

• DLCO of ≥ 25pp at screening.

• Willing and able to complete all protocol required study visits and procedures.

• All participants of childbearing potential must have a negative serum pregnancy test at Screening.

• Participants with reproductive potential must agree to use and follow medically approved contraceptive precautions during the study